These results were validated in an independent AML dataset of 160 samples available from The Cancer Genome Atlas (TCGA) project which comprised 7 samples with t(8;21), 12 with inv(16), 11 with MLL translocations and normal karyotype AML with FLT3-ITD (n=22), NPM1 (n=43) or DNMT3A mutations (n=30) (Figure 4c). This evidence concerns the gene NPM1 and acute myeloid leukemia.